Epaned shortage: What providers and prescribers need to know in 2026

Clinicians who prescribe Epaned (enalapril maleate oral solution, 1 mg/mL) for pediatric hypertension or for adults with swallowing difficulties are increasingly encountering patient-reported access problems in 2026. While Epaned is not on the FDA's official drug shortage list, its niche position in the market — brand-only, low-volume, limited pharmacy stocking — creates genuine barriers for patients trying to fill their prescriptions.

Understanding the landscape helps you anticipate problems, counsel patients effectively, and have appropriate alternatives ready when needed.

Current Availability Status: What We Know

As of 2026, Epaned oral solution is not listed on the FDA drug shortage database, nor is it flagged by ASHP as a current shortage. However, the practical picture differs from the regulatory one:

Many community and chain pharmacies do not routinely stock Epaned; it is treated as a special-order item.

Generic enalapril oral solution availability at the retail level remains inconsistent, despite FDA approval.

Insurance coverage for Epaned is limited — most Medicare and many commercial plans do not cover it — which pushes patients toward compounded alternatives or abandonment of therapy.

Rural patients and those in areas with fewer pharmacy options face the greatest barriers.

Clinical Context: Who Is Prescribed Epaned?

Epaned is FDA-approved for three indications:

Hypertension in adults and children older than one month. This is its primary use in pediatrics, where accurate weight-based dosing is essential.

Symptomatic heart failure in adults. Used when swallowing tablets is difficult due to dysphagia, debility, or patient preference.

Asymptomatic left ventricular dysfunction in adults. Indicated to reduce the rate of development of overt heart failure and reduce hospitalization.

The pediatric population is of particular clinical concern. Infants and young children requiring precise liquid dosing cannot easily substitute to an alternative formulation without careful consideration of dose accuracy and formulation quality.

Dosing Reminders for the Oral Solution

Adults (hypertension): Initial dose 5 mg once daily; titrate to response; maximum 40 mg/day. Start at 2.5 mg/day if eGFR ≤30 mL/min/1.73 m² or on dialysis.

Adults (heart failure): Initial dose 2.5 mg twice daily; titrate to maximum 10 mg twice daily as tolerated.

Pediatric (>1 month, hypertension): 0.08 mg/kg once daily (up to 5 mg). Not recommended in patients with eGFR <30 mL/min/1.73 m² or neonates.

Therapeutic Alternatives: Clinical Decision Framework

When Epaned is unavailable or cost-prohibitive, the following alternatives should be considered based on patient-specific factors:

Compounded enalapril oral suspension (preferred for continuity): Preserves the same active ingredient and allows weight-based dosing. Specify concentration (1 mg/mL), flavoring, and suspension vehicle in the prescription. Use an accredited (PCAB) compounding pharmacy.

Qbrelis (lisinopril 1 mg/mL oral solution): FDA-approved liquid ACE inhibitor; generally more widely available and better covered by insurance. Not directly interchangeable dose-for-dose with enalapril; prescribe based on lisinopril dosing guidelines.

Generic enalapril tablets (for adults who can swallow): Broadly available, low-cost. Widely covered by insurance. Appropriate if the liquid formulation was used for convenience rather than medical necessity.

ARBs (losartan, valsartan) if ACE inhibitor cough is an issue: If the patient is transitioning due to intolerance rather than availability, ARBs provide an alternative mechanism. Losartan oral suspension can be compounded for pediatric use.

39,483+ patients found their medications in stock

39K+

Find Epaned In Stock Today →

Safety Considerations When Switching Formulations

Monitor blood pressure closely for 1–2 weeks after any formulation change to ensure equivalent therapeutic effect.

When switching drug class (e.g., enalapril to lisinopril), calculate the equivalent dose using lisinopril dosing references — not a 1:1 conversion.

For pediatric patients, document the switch, new formulation, and dose in the chart. Recheck renal function and serum potassium at the follow-up visit.

Boxed warning applies to all ACE inhibitors: discontinue immediately upon pregnancy detection.

How to Help Your Patients Find Epaned

Refer patients to medfinder for providers — a service that calls pharmacies on the patient's behalf to find which ones can fill the prescription and texts results directly to the patient. This eliminates the patient burden of calling pharmacy after pharmacy and reduces the risk of gaps in therapy due to availability frustration.

Skip the calls, skip the stress.

Find Epaned In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Key Takeaways for Providers

Epaned is not in a formal FDA shortage but has consistent, patient-reported access barriers due to limited pharmacy stocking.

Compounded enalapril suspension is the best alternative when continuity of drug is preferred.

Qbrelis (lisinopril oral solution) is typically more accessible and better covered by insurance.

Anticipate insurance prior authorization requirements and have a plan for patients without coverage.

Refer patients to medfinder to locate in-stock pharmacies without burdening your office staff.